085 Factors Associated with Long-Term Rituximab Use in Rheumatoid Arthritis: Results from the British Society for Rheumatology Biologics Register
Alexander Oldroyd(Manchester Academic Health Science Centre), Kimme L Hyrich(Manchester Royal Infirmary), Deborah Symmons(University of Manchester), Jamie C. Sergeant(Manchester Academic Health Science Centre), Mark Lunt(University of Cambridge), Lianne Kearsley‐Fleet(University of Manchester), Kath Watson(University of Manchester)
Cited by 0
Related Papers
Prediction models for diagnosis and prognosis of covid-19: systematic review and critical appraisal
|BMJ|2020|3.3k
EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2022 update
|Annals of the Rheumatic Diseases|2022|1.9k
Drug-specific risk of tuberculosis in patients with rheumatoid arthritis treated with anti-TNF therapy: results from the British Society for Rheumatology Biologics Register (BSRBR)
|Annals of the Rheumatic Diseases|2009|708
High-density genetic mapping identifies new susceptibility loci for rheumatoid arthritis
|Nature Genetics|2012|677
EULAR definition of difficult-to-treat rheumatoid arthritis
|Annals of the Rheumatic Diseases|2020|538